Prognos Health leverages clinical and analytical expertise to transform diagnostic and transactional data into insight-ready information, with a focus on unlocking the power of data to improve health.

Prognos Health is a real-world data (RWD) company that unlocks the power of data to improve health. Prognos offers the leading managed RWD marketplace, accelerating the development and delivery of innovative therapies and improving health outcomes by offering fully integrated and harmonized lab and health records on more than 325 million de-identified patients. Prognos Health's platform provides a comprehensive and integrated view of patient health, enabling researchers, payers, and providers to make better decisions about care.

Safeguard Scientifics

MentorTech Ventures

Merck Global Health Innovation Fund

Cigna

Guardian Life

Hermed Capital

Hikma Ventures

Maywic Select Investments

Red & Blue Ventures

Hunt Holdings

LabCorp

Marshall Wace

Merck

Prognos Health

Prognos Health is excited to announce the launch of Prognos Oncology, giving life sciences and pharmaceutical customers unprecedented access to cancer diagnostics data. This powerful platform empowers pharmaceutical companies to achieve excellence in commercial launch planning and activation, ultimately expediting access to life-saving therapies for patients in need. Learn more here: https://bit.ly/496TuPd

To hear the details about this unique and exclusive offering, join Prog Mark Reis in partnership with the Genomic Testing Cooperative tomorrow, February 8, 2024 at 11:00am Eastern Time / 8:00am Pacific Time for a webinar. Register here to attend and receive event recording: https://bit.ly/3usLAkj 

This launch furthers our mission to unlock the power of data to improve health across complex clinical populations facing challenging and life-altering conditions.

#healthcareinnovation #rwd #healthoutcomes #realworlddata 

This Thursday! Don't miss out... 

Join us with the Genomic Testing Cooperative on February 8 at 11:00am EST / 8:00am PST to discuss trends in cancer diagnostics and how Advancements in Comprehensive Genomic Profiling (CGP) and Next Generation Sequencing (NGS) are driving personalized medicine and the adoption of targeted therapies for individual patients in cancer care today.

Register here: February 8: Webinar with the Genomic Testing Cooperative https://bit.ly/3HMnDr8

Unable to attend? Use the form above and indicate "send me the recording" and we'll send the webinar your way in 48 hours. 

Join us with the Genomic Testing Cooperative on February 8 at 11:00am EST / 8:00am PST to discuss trends in cancer diagnostics and how Advancements in Comprehensive Genomic Profiling (CGP) and Next Generation Sequencing (NGS) are driving personalized medicine and the adoption of targeted therapies for individual patients in cancer care today.

Register here: February 8: Webinar with the Genomic Testing Cooperative https://bit.ly/48N0Xms

Mark Reis Jeffrey Owen Ahmad Charifa

Prognos provides independent and scientifically validated analyses for companies, associations, foundations, and public clients. The company was founded in 1959 and specializes in economic, societal, and environmental studies.

COM:PROGNOSHEALTH

Prognos

Analysis Not Available